FDA approves Takeda's Dexilant SoluTab to treat gastroesophageal reflux disease

The US Food and Drug Administration (FDA) has granted approval for Takeda Pharmaceuticals' Dexilant SoluTab delayed-release orally disintegrating tablets to treat adults with heartburn associated with Gastroesophageal Reflux Disease (GERD), a chronic…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news